Phase III, Randomized, Double-Blind, Placebo-Controlled Evaluation of Pregabalin for Alleviating Hot Flashes, N07C1

2009162 citationsJournal Articlebronze Open Access

Authors

Charles L. Loprinzi · Columbus Community Clinical Oncology Program

Rui Qin · Columbus Community Clinical Oncology Program

Ernie P. Baclueva · Columbus Community Clinical Oncology Program

Kathleen Flynn · Columbus Community Clinical Oncology Program

Kendrith M. Rowland · Columbus Community Clinical Oncology Program

David L. Graham · Columbus Community Clinical Oncology Program

Abstract

Pregabalin decreases hot flashes and is reasonably well tolerated. A target dose of 75 mg twice daily is recommended. Its effects appear to be roughly comparable to what has been reported with gabapentin and with some newer antidepressants.

Topics & Keywords

Treatment of Major Depression Pain Mechanisms and Treatments Cardiac electrophysiology and arrhythmias

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 28, Issue 4, pp. 641-647

DOI: 10.1200/jco.2009.24.5647

Field-Weighted Citation Impact: 7.77